CNS Pharmaceuticals (CNSP) EBIT Growth (1y) (2019 - 2025)
CNS Pharmaceuticals (CNSP) EBIT Growth (1y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | -87.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -87.06% |
| Sep 30, 2025 | 42.20% |
| Jun 30, 2025 | 4.70% |
| Mar 31, 2025 | -22.36% |
| Dec 31, 2024 | 40.51% |
| Sep 30, 2024 | -24.15% |
| Jun 30, 2024 | 37.20% |
| Mar 31, 2024 | 28.05% |
| Dec 31, 2023 | -4.77% |
| Sep 30, 2023 | -32.61% |
| Jun 30, 2023 | -12.93% |
| Mar 31, 2023 | -56.44% |
| Dec 31, 2022 | -57.91% |
| Sep 30, 2022 | 10.34% |
| Jun 30, 2022 | 6.48% |
| Mar 31, 2022 | 12.76% |
| Dec 31, 2021 | -8.33% |
| Sep 30, 2021 | -89.62% |
| Jun 30, 2021 | -54.07% |
| Mar 31, 2021 | -83.41% |